- Home
- MANH vs RDY Comparison
MANH vs RDY Comparison
Compare MANH & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- RDY
- Stock Information
- Founded
- MANH 1990
- RDY 1984
- Country
- MANH United States
- RDY India
- Employees
- MANH N/A
- RDY N/A
- Industry
- MANH Computer Software: Prepackaged Software
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- MANH Technology
- RDY Health Care
- Exchange
- MANH Nasdaq
- RDY Nasdaq
- Market Cap
- MANH 12.0B
- RDY 12.1B
- IPO Year
- MANH 1998
- RDY N/A
- Fundamental
- Price
- MANH $214.66
- RDY $13.94
- Analyst Decision
- MANH Buy
- RDY Strong Buy
- Analyst Count
- MANH 9
- RDY 2
- Target Price
- MANH $221.25
- RDY $16.95
- AVG Volume (30 Days)
- MANH 663.1K
- RDY 1.6M
- Earning Date
- MANH 07-22-2025
- RDY 07-23-2025
- Dividend Yield
- MANH N/A
- RDY 0.51%
- EPS Growth
- MANH 9.17
- RDY 2.20
- EPS
- MANH 3.58
- RDY 0.79
- Revenue
- MANH $1,057,690,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- MANH $4.95
- RDY $7.61
- Revenue Next Year
- MANH $6.76
- RDY $1.89
- P/E Ratio
- MANH $59.96
- RDY $17.57
- Revenue Growth
- MANH 6.13
- RDY 15.86
- 52 Week Low
- MANH $140.81
- RDY $12.26
- 52 Week High
- MANH $312.60
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- MANH 57.34
- RDY 33.24
- Support Level
- MANH $218.81
- RDY $14.00
- Resistance Level
- MANH $229.58
- RDY $14.86
- Average True Range (ATR)
- MANH 7.57
- RDY 0.24
- MACD
- MANH 0.93
- RDY -0.06
- Stochastic Oscillator
- MANH 36.96
- RDY 9.13
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.